Picking Pharmaceutical Funds: Portfolio, Risk and Cost Guide

India's pharmaceutical sector has attracted significant investor interest in recent years, with dedicated mutual funds and investment vehicles offering exposure to drugmakers, healthcare services and related enterprises. However, selecting the right pharma fund requires careful analysis beyond simple performance numbers, according to investment professionals tracking the space.

Investors evaluating pharmaceutical funds should prioritize examining the underlying portfolio composition—whether holdings focus on large-cap established players, mid-cap manufacturers, or specialty pharmaceutical companies. Risk assessment remains equally critical, with metrics such as standard deviation and volatility measures helping investors understand potential price swings. The expense ratio, or annual costs charged by fund managers, can significantly erode long-term returns and warrants close comparison across competing options.

Expertise in the healthcare and pharmaceutical sector also distinguishes fund managers, as sector-specific knowledge helps in identifying sustainable competitive advantages and regulatory headwinds that may impact company valuations. Investors should review whether fund managers possess demonstrated track records in evaluating pharmaceutical businesses and navigating industry cycles.

Given the sector's sensitivity to regulatory changes, drug approvals, and patent expirations, financial advisors generally recommend maintaining a modest allocation to pharmaceutical funds within broader portfolios. A multi-year investment horizon allows investors to ride out short-term volatility while capturing potential growth from India's expanding domestic pharmaceutical industry and rising healthcare consumption.